The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

##STR00001##

The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

##STR00001##

The present specification relates to a heterocyclic compound of Chemical Formula 1, and an organic light emitting device including the same. The heterocyclic compound as a material of an organic material layer of the organic light emitting device provides enhanced efficiency, low driving voltage and enhanced lifetime properties.

##STR00001##

The present specification relates to a heterocyclic compound of Chemical Formula 1, and an organic light emitting device including the same. The heterocyclic compound as a material of an organic material layer of the organic light emitting device provides enhanced efficiency, low driving voltage and enhanced lifetime properties.

##STR00001##

Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing and/or treating central nervous system diseases related to 5-hydroxytryptamine receptors and/or trace amine-related receptors and/or dopamine receptors in mammals.

##STR00001##

Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing and/or treating central nervous system diseases related to 5-hydroxytryptamine receptors and/or trace amine-related receptors and/or dopamine receptors in mammals.

##STR00001##

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, ##STR00001##
and the variables R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, ##STR00001##
and the variables R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.